clinical trials

News

INmune Bio slumps on midstage fail for Alzheimer's drug

INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.

News

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

Sales & Marketing

12 Questions with Chris Venezia

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

Nuvalent chases after Nuvation in ROS1 lung cancer

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

News

ADA: Vertex closer to weaning type 1 diabetics off insulin

A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.

INmune Bio slumps on midstage fail for Alzheimer's drug

Nektar eyes pivotal trials for eczema drug cast off by Lilly

12 Questions with Chris Venezia

Biogen races into phase 3 with Spinraza follow-up

Nuvalent chases after Nuvation in ROS1 lung cancer

ADA: Vertex closer to weaning type 1 diabetics off insulin

Kyverna builds case for CAR-T in stiff person syndrome

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks